Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
National Institute of Neurological Disorders and Stroke (NINDS)
The objective of this study is to evaluate the acute effects of the putative NMDA-receptor antagonist amantadine on chorea of patients with Huntington's disease (HD). Participants in this study will have mild to moderate HD associated with chorea.
Age
Any age
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
All patients will carry a diagnosis of Huntington's disease confirmed by DNA testing.
Patients will have mild to moderate disease with associated significant chorea.
Ability to comply with study requirements and to report on their condition by telephone.
Males and females between the ages of 18 and 82.
No patients with the presence or history of any medical condition that can reasonably be expected to subject the patient to unwarranted risk.
No patients with renal impairment (serum creatinine exceeding the upper limit of normal).
No patients with a history of intolerance to previous exposure to amantadine.
No patients with an MMSE of less than 18/30.
No patients receiving other anti-chorea therapies (such as Haldol). Those receiving other anti-chorea therapies must stop taking these medications for at least 4 weeks prior to the study to be eligible.
No pregnant women.
Patients must practice effective means of birth control.
